BioPharmSignal logoBioPharmSignal

Biotech News

Centessa Pharmaceuticals Announces Poster Presentation of New Preclinical Data Supporting Expansion of Orexin Receptor 2 (OX2R) Agonist Pipeline into Neuropsychiatric Indications at the 64th ACNP Annual Meeting

Centessa Pharmaceuticals (CNTA)Centessa PharmaceuticalsConference / presentation

Antidepressive effects and enhanced wakefulness were observed with OX2R activation in established animal model of major depressive disorder BOSTON and LONDON, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company focused on developing

Related news

CNTACentessa Pharmaceuticals2025-09-03 11:00 EST

Centessa Pharmaceuticals to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference

CNTACentessa Pharmaceuticals2025-11-05 12:00 EST

Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2025 and Provides Update on Potential Best-in-Class Orexin Receptor 2 (OX2R) Agonist Program

View all latest news

Centessa Pharmaceuticals

Centessa Pharmaceuticals is a platform biopharma company incubating focused therapeutic programs across multiple disease areas. Its model emphasizes capital allocation, program selection, and broad platform optionality.

Recent company news

CNTACentessa Pharmaceuticals2026-03-31 10:45 EST

Lilly to acquire Centessa Pharmaceuticals to advance treatments for sleep-wake disorders

CNTACentessa Pharmaceuticals2026-02-03 13:00 EST

Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences

CNTACentessa Pharmaceuticals2026-01-14 22:00 EST

Centessa Pharmaceuticals Announces Poster Presentation of New Preclinical Data Supporting Expansion of Orexin Receptor 2 (OX2R) Agonist Pipeline into Neuropsychiatric Indications at the 64th ACNP Annual Meeting

CNTACentessa Pharmaceuticals2025-12-11 12:00 EST

Centessa Pharmaceuticals Announces CEO Transition as Company Advances Strategy to Extend Orexin Leadership into Multiple Neuroscience Indications

CNTACentessa Pharmaceuticals2025-11-12 01:40 EST

Centessa Pharmaceuticals Announces Pricing of $250,000,000 Public Offering of American Depositary Shares

Stock data

Close
40.50 USD
Market cap
6.17B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States